High-Dose Cytarabine for Acute Myeloid Leukemia

AML patients with mutant RAS oncogenes had lower rates of relapse than did those with wild-type RAS.

De novo acute myeloid leukemia (AML) is a heterogeneous clinical disorder characterized by a variety of cytogenetic abnormalities and gene mutations (e.g., FLT3 or NPM1) that correlate with complete remission following induction chemotherapy, as well as with overall survival (JW Oncol Hematol May 13 2008). Mutations in the RAS oncogene (mutRAS) also have been reported in AML, with these cells showing enhanced cytarabine sensitivity in vitro (Cancer Res 1999; 59:6057).

Investigators performed a retrospective analysis of 185 adult de novo AML patients who participated in the Cancer and Leukemia Group B (CALGB) 8525 clinical trial (N Engl J Med 1994; 331:896) of induction chemotherapy with daunorubicin plus cytarabine. Patients who achieved com…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee